{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T04:10:18Z","timestamp":1782965418016,"version":"3.54.5"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP25K10091"],"award-info":[{"award-number":["JP25K10091"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the KOS\u00b4E Cosmetology Research Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"DOI":"10.1007\/s00280-026-04915-8","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T03:42:32Z","timestamp":1782963752000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Composition and structure of stratum corneum intercellular lipids in patients with osimertinib-induced hand-foot syndrome"],"prefix":"10.1007","volume":"96","author":[{"given":"Michiaki","family":"Nakajo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8667-9365","authenticated-orcid":false,"given":"Tomonobu","family":"Uchino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Asada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Hatta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuji","family":"Yumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayuko","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuna","family":"Iwano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yui","family":"Nabekura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasunori","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanami","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tasuku","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyuki","family":"Kagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiki","family":"Tsuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,2]]},"reference":[{"key":"4915_CR1","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/nrc3775","volume":"14","author":"Z Chen","year":"2014","unstructured":"Chen Z, Fillmore CM, Hammerman PS et al (2014) Non-small-cell lung cancers: a heterogeneous set of diseases. Nat Rev Cancer 14:535\u2013546. https:\/\/doi.org\/10.1038\/nrc3775","journal-title":"Nat Rev Cancer"},{"key":"4915_CR2","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1056\/NEJMoa050736","volume":"353","author":"T Ming-Sound","year":"2025","unstructured":"Ming-Sound T, Akira S, Jean-Claude C et al (2025) Erlotinib in Lung Cancer \u2014 Molecular and Clinical Predictors of Outcome. N Engl J Med 353:133\u2013144. https:\/\/doi.org\/10.1056\/NEJMoa050736","journal-title":"N Engl J Med"},{"key":"4915_CR3","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010383.pub3","author":"J Greenhalgh","year":"2021","unstructured":"Greenhalgh J, Boland A, Bates V et al (2021) First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non\u2010squamous non\u2010small cell lung cancer. Cochrane Database Syst Reviews. https:\/\/doi.org\/10.1002\/14651858.CD010383.pub3","journal-title":"Cochrane Database Syst Reviews"},{"key":"4915_CR4","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12943-018-0778-0","volume":"17","author":"C-S Tan","year":"2018","unstructured":"Tan C-S, Kumarakulasinghe NB, Huang Y-Q et al (2018) Third generation EGFR TKIs: current data and future directions. Mol Cancer 17:29. https:\/\/doi.org\/10.1186\/s12943-018-0778-0","journal-title":"Mol Cancer"},{"key":"4915_CR5","doi-asserted-by":"publisher","first-page":"e216","DOI":"10.1016\/j.cllc.2019.12.003","volume":"21","author":"R Shah","year":"2020","unstructured":"Shah R, Lester JF (2020) Tyrosine Kinase Inhibitors for the Treatment of EGFR Mutation-Positive Non\u2013Small-Cell Lung Cancer: A Clash of the Generations. Clin Lung Cancer 21:e216\u2013e228. https:\/\/doi.org\/10.1016\/j.cllc.2019.12.003","journal-title":"Clin Lung Cancer"},{"key":"4915_CR6","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s11523-024-01073-w","volume":"19","author":"S Zhou","year":"2024","unstructured":"Zhou S, Kishi N, Alerasool P, Rohs NC (2024) Adverse Event Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-small Cell Lung Cancer: An Updated Meta-analysis. Target Oncol 19:547\u2013564. https:\/\/doi.org\/10.1007\/s11523-024-01073-w","journal-title":"Target Oncol"},{"key":"4915_CR7","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.jaad.2014.03.019","volume":"71","author":"KK Miller","year":"2014","unstructured":"Miller KK, Gorcey L, McLellan BN (2014) Chemotherapy-induced hand-foot syndrome and nail changes: A review of clinical presentation, etiology, pathogenesis, and management. J Am Acad Dermatol 71:787\u2013794. https:\/\/doi.org\/10.1016\/j.jaad.2014.03.019","journal-title":"J Am Acad Dermatol"},{"key":"4915_CR8","doi-asserted-by":"publisher","first-page":"204209862211019","DOI":"10.1177\/20420986221101963","volume":"13","author":"Y Yoshida","year":"2022","unstructured":"Yoshida Y, Sasaoka S, Tanaka M et al (2022) Analysis of drug-induced hand\u2013foot syndrome using a spontaneous reporting system database. Ther Adv Drug Saf 13:20420986221101964. https:\/\/doi.org\/10.1177\/20420986221101963","journal-title":"Ther Adv Drug Saf"},{"key":"4915_CR9","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1056\/NEJMoa1612674","volume":"376","author":"SMT Yi-Long","year":"2025","unstructured":"Yi-Long SMT, Myung-Ju W A, et al (2025) Osimertinib or Platinum\u2013Pemetrexed in EGFR T790M\u2013Positive Lung Cancer. N Engl J Med 376:629\u2013640. https:\/\/doi.org\/10.1056\/NEJMoa1612674","journal-title":"N Engl J Med"},{"key":"4915_CR10","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/s12885-021-07922-5","volume":"21","author":"M Provencio","year":"2021","unstructured":"Provencio M, Terrasa J, Garrido P et al (2021) Osimertinib in advanced EGFR-T790M mutation-positive non-small cell lung cancer patients treated within the Special Use Medication Program in Spain: OSIREX-Spanish Lung Cancer Group. BMC Cancer 21:230. https:\/\/doi.org\/10.1186\/s12885-021-07922-5","journal-title":"BMC Cancer"},{"key":"4915_CR11","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1046\/j.1523-1747.2002.01706.x","volume":"118","author":"JA Bouwstra","year":"2002","unstructured":"Bouwstra JA, Gooris GS, Dubbelaar FER, Ponec M (2002) Phase behavior of stratum corneum lipid mixtures based on human ceramides: The role of natural and synthetic ceramide 1. J Invest Dermatology 118:606\u2013617. https:\/\/doi.org\/10.1046\/j.1523-1747.2002.01706.x","journal-title":"J Invest Dermatology"},{"key":"4915_CR12","doi-asserted-by":"publisher","unstructured":"van Smeden J, Janssens M, Gooris GS, Bouwstra JA (2014) The important role of stratum corneum lipids for the cutaneous barrier function. Biochim Biophys Acta, Mol Cell Biol Lipids 1841:295. https:\/\/doi.org\/10.1016\/j.bbalip.2013.11.006","DOI":"10.1016\/j.bbalip.2013.11.006"},{"key":"4915_CR13","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.5650\/jos.ess21159","volume":"70","author":"I Hatta","year":"2021","unstructured":"Hatta I, Nakazawa H, Ohta N et al (2021) Stratum Corneum Function: A Structural Study with Dynamic Synchrotron X-ray Diffraction Experiments. J Oleo Sci 70:1181\u20131199. https:\/\/doi.org\/10.5650\/jos.ess21159","journal-title":"J Oleo Sci"},{"key":"4915_CR14","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/0378-5173(92)90158-X","volume":"84","author":"JA Bouwstra","year":"1992","unstructured":"Bouwstra JA, Gooris GS, Salomonsdevries MA et al (1992) Structure of Human Stratum-Corneum as a Function of Temperature and Hydration - a Wide-Angle X-Ray-Diffraction Study. Int J Pharm 84:205\u2013216. https:\/\/doi.org\/10.1016\/0378-5173(92)90158-X","journal-title":"Int J Pharm"},{"key":"4915_CR15","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1111\/ics.12162","volume":"36","author":"M Boncheva","year":"2014","unstructured":"Boncheva M (2014) The physical chemistry of the stratum corneum lipids. Int J Cosmet Sci 36:505\u2013515. https:\/\/doi.org\/10.1111\/ics.12162","journal-title":"Int J Cosmet Sci"},{"key":"4915_CR16","doi-asserted-by":"publisher","first-page":"197","DOI":"10.5650\/jos.60.197","volume":"60","author":"K Aburai","year":"2011","unstructured":"Aburai K, Yoshino S, Sakai K et al (2011) Physicochemical Analysis of Liposome Membranes Consisting of Model Lipids in the Stratum Corneum. Biochem Biotechnol 60:197\u2013202. https:\/\/doi.org\/10.5650\/jos.60.197","journal-title":"Biochem Biotechnol"},{"key":"4915_CR17","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1046\/j.1365-2133.1999.03098.x","volume":"141","author":"M Hern\u00e1ndez","year":"1999","unstructured":"Hern\u00e1ndez M, Gonz\u00e1lez S, De U (1999) X-linked ichthyosis: an update. Br J Dermatol 141:617\u2013627. https:\/\/doi.org\/10.1046\/j.1365-2133.1999.03098.x","journal-title":"Br J Dermatol"},{"key":"4915_CR18","doi-asserted-by":"publisher","first-page":"101252","DOI":"10.1016\/J.PLIPRES.2023.101252","volume":"92","author":"JA Bouwstra","year":"2023","unstructured":"Bouwstra JA, N\u0103d\u0103ban A, Bras W et al (2023) The skin barrier: An extraordinary interface with an exceptional lipid organization. Prog Lipid Res 92:101252. https:\/\/doi.org\/10.1016\/J.PLIPRES.2023.101252","journal-title":"Prog Lipid Res"},{"key":"4915_CR19","doi-asserted-by":"publisher","unstructured":"Suzuki M, Ohno Y, Kihara A (2022) Whole picture of human stratum corneum ceramides, including the chain-length diversity of long-chain bases. J Lipid Res 63. https:\/\/doi.org\/10.1016\/j.jlr.2022.100235","DOI":"10.1016\/j.jlr.2022.100235"},{"key":"4915_CR20","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.1038\/jid.2010.161","volume":"130","author":"J Ishikawa","year":"2010","unstructured":"Ishikawa J, Narita H, Kondo N et al (2010) Changes in the ceramide profile of atopic dermatitis patients. J Invest Dermatology 130:2511\u20132514","journal-title":"J Invest Dermatology"},{"key":"4915_CR21","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/j.1529-8019.2006.00058.x","volume":"19","author":"A Krol","year":"2006","unstructured":"Krol A, Krafchik B (2006) The differential diagnosis of atopic dermatitis in childhood. Dermatol Ther 19:73\u201382. https:\/\/doi.org\/https:\/\/doihttps:\/\/doi.org\/10.1111\/j.1529-8019.2006.00058.x","journal-title":"Dermatol Ther"},{"key":"4915_CR22","doi-asserted-by":"publisher","unstructured":"Van Smeden J, Janssens M, Boiten WA et al (2014) Intercellular Skin Barrier Lipid Composition and Organization in Netherton Syndrome Patients. 134:1238\u20131245. https:\/\/doi.org\/10.1038\/jid.2013.517","DOI":"10.1038\/jid.2013.517"},{"key":"4915_CR23","doi-asserted-by":"publisher","first-page":"105305","DOI":"10.1016\/j.chemphyslip.2023.105305","volume":"254","author":"T Uchino","year":"2023","unstructured":"Uchino T, Kamiya D, Yagi H et al (2023) Comparative analysis of intercellular lipid organization and composition between psoriatic and healthy stratum corneum. Chem Phys Lipids 254:105305. https:\/\/doi.org\/10.1016\/j.chemphyslip.2023.105305","journal-title":"Chem Phys Lipids"},{"key":"4915_CR24","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s00280-020-04095-z","volume":"86","author":"T Uchino","year":"2020","unstructured":"Uchino T, Fujino H, Kamiya D et al (2020) Association of dry skin with intercellular lipid composition of stratum corneum after erlotinib administration. Cancer Chemother Pharmacol 86:233\u2013243. https:\/\/doi.org\/10.1007\/s00280-020-04095-z","journal-title":"Cancer Chemother Pharmacol"},{"key":"4915_CR25","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s00280-025-04842-0","volume":"96","author":"T Uchino","year":"2026","unstructured":"Uchino T, Nakajo M, Hatta I et al (2026) Analysis of intercellular lipids in the stratum corneum of patients with capecitabine-induced hand-foot syndrome: comparison with the stratum corneum of healthy individuals. Cancer Chemother Pharmacol 96:8. https:\/\/doi.org\/10.1007\/s00280-025-04842-0","journal-title":"Cancer Chemother Pharmacol"},{"key":"4915_CR26","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/0925-4439(93)90135-n","volume":"1182","author":"S Motta","year":"1993","unstructured":"Motta S, Monti M, Sesana S et al (1993) Ceramide composition of the psoriatic scale. Biochimica et Biophysica Acta (BBA) -. Mol Basis Disease 1182:147\u2013151. https:\/\/doi.org\/10.1016\/0925-4439(93)90135-n","journal-title":"Mol Basis Disease"},{"key":"4915_CR27","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1194\/jlr.m800014-jlr200","volume":"49","author":"Y Masukawa","year":"2008","unstructured":"Masukawa Y, Narita H, Shimizu E et al (2008) Characterization of overall ceramide species in humanstratum corneum. J Lipid Res 49:1466\u20131476. https:\/\/doi.org\/10.1194\/jlr.m800014-jlr200","journal-title":"J Lipid Res"},{"key":"4915_CR28","doi-asserted-by":"publisher","first-page":"13794","DOI":"10.1021\/acs.langmuir.4c00554","volume":"40","author":"A N\u0103d\u0103ban","year":"2024","unstructured":"N\u0103d\u0103ban A, Frame CO, El Yachioui D et al (2024) The Sphingosine and Phytosphingosine Ceramide Ratio in Lipid Models Forming the Short Periodicity Phase: An Experimental and Molecular Simulation Study. Langmuir 40:13794\u201313809. https:\/\/doi.org\/10.1021\/acs.langmuir.4c00554","journal-title":"Langmuir"},{"key":"4915_CR29","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12895-020-00102-1","volume":"20","author":"U Yokose","year":"2020","unstructured":"Yokose U, Ishikawa J, Morokuma Y et al (2020) The ceramide [NP]\/[NS] ratio in the stratum corneum is a potential marker for skin properties and epidermal differentiation. BMC Dermatol 20:6. https:\/\/doi.org\/10.1186\/s12895-020-00102-1","journal-title":"BMC Dermatol"},{"key":"4915_CR30","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/jocd.12019","volume":"12","author":"J Ishikawa","year":"2013","unstructured":"Ishikawa J, Yoshida H, Ito S et al (2013) Dry skin in the winter is related to the ceramide profile in the stratum corneum and can be improved by treatment with a Eucalyptus extract. J Cosmet Dermatol 12:3\u201311. https:\/\/doi.org\/10.1111\/jocd.12019","journal-title":"J Cosmet Dermatol"},{"key":"4915_CR31","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1111\/1523-1747.ep12492217","volume":"97","author":"JA Bouwstra","year":"1991","unstructured":"Bouwstra JA, Gooris GS, van der Spek JA, Bras W (1991) Structural investigations of human stratum corneum by small-angle X-ray scattering. J Invest Dermatology 97:1005\u20131012. https:\/\/doi.org\/10.1111\/1523-1747.ep12492217","journal-title":"J Invest Dermatology"},{"key":"4915_CR32","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1111\/1523-1747.ep12264708","volume":"83","author":"LB Nanney","year":"1984","unstructured":"Nanney LB, Magid M, Stoscheck CM, King LE (1984) Comparison of Epidermal Growth Factor Binding and Receptor Distribution in Normal Human Epidermis and Epidermal Appendages. J Invest Dermatology 83:385\u2013393. https:\/\/doi.org\/10.1111\/1523-1747.ep12264708","journal-title":"J Invest Dermatology"},{"key":"4915_CR33","doi-asserted-by":"publisher","first-page":"3080","DOI":"10.1200\/JCO.2004.08.189","volume":"22","author":"AR Tan","year":"2004","unstructured":"Tan AR, Yang X, Hewitt SM et al (2004) Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor. J Clin Oncol 22:3080\u20133090. https:\/\/doi.org\/10.1200\/JCO.2004.08.189","journal-title":"J Clin Oncol"},{"key":"4915_CR34","doi-asserted-by":"publisher","first-page":"4292","DOI":"10.1200\/JCO.2002.03.100","volume":"20","author":"J Baselga","year":"2002","unstructured":"Baselga J, Rischin D, Ranson M et al (2002) Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 20:4292\u20134302. https:\/\/doi.org\/10.1200\/JCO.2002.03.100","journal-title":"J Clin Oncol"},{"key":"4915_CR35","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.plipres.2016.04.001","volume":"63","author":"A Kihara","year":"2016","unstructured":"Kihara A (2016) Synthesis and degradation pathways, functions, and pathology of ceramides and epidermal acylceramides. Prog Lipid Res 63:50\u201369. https:\/\/doi.org\/10.1016\/j.plipres.2016.04.001","journal-title":"Prog Lipid Res"},{"key":"4915_CR36","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1038\/nrendo.2017.91","volume":"13","author":"H Shimano","year":"2017","unstructured":"Shimano H, Sato R (2017) SREBP-regulated lipid metabolism: convergent physiology \u2014 divergent pathophysiology. Nat Rev Endocrinol 13:710\u2013730. https:\/\/doi.org\/10.1038\/nrendo.2017.91","journal-title":"Nat Rev Endocrinol"},{"key":"4915_CR37","doi-asserted-by":"publisher","first-page":"857","DOI":"10.3168\/jds.2020-19292","volume":"465","author":"A Shikama","year":"2015","unstructured":"Shikama A, Shinozaki H, Takeuchi Y et al (2015) ELOVL6 promoter binding sites directly targeted by sterol regulatory element binding protein 1 in fatty acid synthesis of goat mammary epithelial cells. Biochem Biophys Res Commun 465:857\u2013863. https:\/\/doi.org\/10.3168\/jds.2020-19292","journal-title":"Biochem Biophys Res Commun"},{"key":"4915_CR38","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1111\/exd.14538","volume":"31","author":"J-H Oh","year":"2022","unstructured":"Oh J-H, Hur W, Li N, Jo SJ (2022) Effects of the epidermal growth factor receptor inhibitor, gefitinib, on lipid and hyaluronic acid synthesis in cultured HaCaT keratinocytes. Exp Dermatol 31:918\u2013927. https:\/\/doi.org\/10.1111\/exd.14538","journal-title":"Exp Dermatol"},{"key":"4915_CR39","doi-asserted-by":"publisher","first-page":"6653","DOI":"10.1038\/s41388-021-02057-0","volume":"40","author":"Z Chen","year":"2021","unstructured":"Chen Z, Yu D, Owonikoko TK et al (2021) Induction of SREBP1 degradation coupled with suppression of SREBP1-mediated lipogenesis impacts the response of EGFR mutant NSCLC cells to osimertinib. Oncogene 40:6653\u20136665. https:\/\/doi.org\/10.1038\/s41388-021-02057-0","journal-title":"Oncogene"},{"key":"4915_CR40","doi-asserted-by":"publisher","first-page":"158840","DOI":"10.1016\/j.bbalip.2020.158840","volume":"1866","author":"RA Igal","year":"2021","unstructured":"Igal RA, Sinner DI (2021) Stearoyl-CoA desaturase 5 (SCD5), a \u2206-9 fatty acyl desaturase in search of a function. Biochimica et Biophysica Acta (BBA) - Molecular and Cell. Biology Lipids 1866:158840. https:\/\/doi.org\/10.1016\/j.bbalip.2020.158840","journal-title":"Biology Lipids"},{"key":"4915_CR41","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1038\/jid.2011.175","volume":"131","author":"M Janssens","year":"2011","unstructured":"Janssens M, Van Smeden J, Gooris GS et al (2011) Lamellar lipid organization and ceramide composition in the stratum corneum of patients with atopic eczema. J Invest Dermatology 131:2136\u20132138. https:\/\/doi.org\/10.1038\/jid.2011.175","journal-title":"J Invest Dermatology"},{"key":"4915_CR42","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.addr.2003.10.025","volume":"56","author":"AC Williams","year":"2004","unstructured":"Williams AC, Barry BW (2004) Penetration enhancers. Adv Drug Deliv Rev 56:603\u2013618. https:\/\/doi.org\/https:\/\/doi.https:\/\/doi.org\/10.1016\/j.addr.2003.10.025","journal-title":"Adv Drug Deliv Rev"},{"key":"4915_CR43","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.21873\/anticanres.16944","volume":"44","author":"ME DARVIN","year":"2024","unstructured":"DARVIN ME, LADEMANN J, JUNG S (2024) Dual Role of Stratum Corneum Carotenes\/Lycopene Against the Development of Chemotherapy-induced PPE in Patients With Cancer. Anticancer Res 44:1487. https:\/\/doi.org\/10.21873\/anticanres.16944","journal-title":"Anticancer Res"},{"key":"4915_CR44","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1111\/j.1365-2133.2007.08357.x","volume":"158","author":"C Yang","year":"2008","unstructured":"Yang C, Lin W, Chuang C et al (2008) Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy. Br J Dermatol 158:592\u2013596. https:\/\/doi.org\/10.1111\/j.1365-2133.2007.08357.x","journal-title":"Br J Dermatol"},{"key":"4915_CR45","doi-asserted-by":"publisher","unstructured":"Jain L, Gardner ER, Figg WD et al (2010) Lack of Association Between Excretion of Sorafenib in Sweat and Hand-Foot Skin Reaction. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 30:52\u201356. https:\/\/doi.org\/10.1592\/phco.30.1.52","DOI":"10.1592\/phco.30.1.52"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-026-04915-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-026-04915-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-026-04915-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T03:42:35Z","timestamp":1782963755000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-026-04915-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4915"],"URL":"https:\/\/doi.org\/10.1007\/s00280-026-04915-8","relation":{},"ISSN":["1432-0843"],"issn-type":[{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,2]]},"assertion":[{"value":"18 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study protocol was approved by the Institutional Review Board of Shizuoka General Hospital (approval number: SGHIRB#2020084) and the University of Shizuoka (approval number: 2\u201354). Informed consent was obtained from all the participants.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent for participation"}}],"article-number":"68"}}